Use of low-dose OKT3 as induction therapy in liver transplantation

James F. Whiting, Annie Fecteau, Jill Martin, Pablo A. Bejarano, Douglas W. Hanto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background. A pilot study was performed to prospectively evaluate the safety and efficacy of 'low-lose ORTS induction after liver transplantation. Methods. Sixteen patients received a 5- to 10-day course of OKTS (2.5 mg i.v. daily) along with azathioprine, prednisone, and the delayed introduction of cyclosporine (Neoral). Results. Patient and graft survival rates at 1 year were 88% and 82%. Five patients (31%) heal biopsyproven rejection; all five were treated successfully with steroids. There were 15 infections in 12 patients including 5 cytomegalovirus infections. Adverse events attributed to OKT3 consisted of low-grade fever (five patients), transient hypoxemia (three patients), and transient hypotension (two patients). Pharmacy aquisition costs for OKT3 averaged $ 2,139 less as compared to a group of historical controls receiving full-dose therapy. Conclusions. Low-dose OKT3 induction appears to be safe and useful method of postoperative immunosuppression after liver transplantation. Its ultimate clinical, immunologic, and ecomic effecacy awaits determination by randomized trial.

Original languageEnglish
Pages (from-to)577-580
Number of pages4
JournalTransplantation
Volume65
Issue number4
DOIs
StatePublished - Feb 27 1998

Fingerprint

Muromonab-CD3
Liver Transplantation
Therapeutics
Cyclosporine
Azathioprine
Cytomegalovirus Infections
Graft Survival
Prednisone
Hypotension
Immunosuppression
Fever
Survival Rate
Steroids
Safety
Costs and Cost Analysis
Control Groups
Infection

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Whiting, J. F., Fecteau, A., Martin, J., Bejarano, P. A., & Hanto, D. W. (1998). Use of low-dose OKT3 as induction therapy in liver transplantation. Transplantation, 65(4), 577-580. https://doi.org/10.1097/00007890-199802270-00022

Use of low-dose OKT3 as induction therapy in liver transplantation. / Whiting, James F.; Fecteau, Annie; Martin, Jill; Bejarano, Pablo A.; Hanto, Douglas W.

In: Transplantation, Vol. 65, No. 4, 27.02.1998, p. 577-580.

Research output: Contribution to journalArticle

Whiting, JF, Fecteau, A, Martin, J, Bejarano, PA & Hanto, DW 1998, 'Use of low-dose OKT3 as induction therapy in liver transplantation', Transplantation, vol. 65, no. 4, pp. 577-580. https://doi.org/10.1097/00007890-199802270-00022
Whiting JF, Fecteau A, Martin J, Bejarano PA, Hanto DW. Use of low-dose OKT3 as induction therapy in liver transplantation. Transplantation. 1998 Feb 27;65(4):577-580. https://doi.org/10.1097/00007890-199802270-00022
Whiting, James F. ; Fecteau, Annie ; Martin, Jill ; Bejarano, Pablo A. ; Hanto, Douglas W. / Use of low-dose OKT3 as induction therapy in liver transplantation. In: Transplantation. 1998 ; Vol. 65, No. 4. pp. 577-580.
@article{f4adf60977fd473fb5457fe929998efe,
title = "Use of low-dose OKT3 as induction therapy in liver transplantation",
abstract = "Background. A pilot study was performed to prospectively evaluate the safety and efficacy of 'low-lose ORTS induction after liver transplantation. Methods. Sixteen patients received a 5- to 10-day course of OKTS (2.5 mg i.v. daily) along with azathioprine, prednisone, and the delayed introduction of cyclosporine (Neoral). Results. Patient and graft survival rates at 1 year were 88{\%} and 82{\%}. Five patients (31{\%}) heal biopsyproven rejection; all five were treated successfully with steroids. There were 15 infections in 12 patients including 5 cytomegalovirus infections. Adverse events attributed to OKT3 consisted of low-grade fever (five patients), transient hypoxemia (three patients), and transient hypotension (two patients). Pharmacy aquisition costs for OKT3 averaged $ 2,139 less as compared to a group of historical controls receiving full-dose therapy. Conclusions. Low-dose OKT3 induction appears to be safe and useful method of postoperative immunosuppression after liver transplantation. Its ultimate clinical, immunologic, and ecomic effecacy awaits determination by randomized trial.",
author = "Whiting, {James F.} and Annie Fecteau and Jill Martin and Bejarano, {Pablo A.} and Hanto, {Douglas W.}",
year = "1998",
month = "2",
day = "27",
doi = "10.1097/00007890-199802270-00022",
language = "English",
volume = "65",
pages = "577--580",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Use of low-dose OKT3 as induction therapy in liver transplantation

AU - Whiting, James F.

AU - Fecteau, Annie

AU - Martin, Jill

AU - Bejarano, Pablo A.

AU - Hanto, Douglas W.

PY - 1998/2/27

Y1 - 1998/2/27

N2 - Background. A pilot study was performed to prospectively evaluate the safety and efficacy of 'low-lose ORTS induction after liver transplantation. Methods. Sixteen patients received a 5- to 10-day course of OKTS (2.5 mg i.v. daily) along with azathioprine, prednisone, and the delayed introduction of cyclosporine (Neoral). Results. Patient and graft survival rates at 1 year were 88% and 82%. Five patients (31%) heal biopsyproven rejection; all five were treated successfully with steroids. There were 15 infections in 12 patients including 5 cytomegalovirus infections. Adverse events attributed to OKT3 consisted of low-grade fever (five patients), transient hypoxemia (three patients), and transient hypotension (two patients). Pharmacy aquisition costs for OKT3 averaged $ 2,139 less as compared to a group of historical controls receiving full-dose therapy. Conclusions. Low-dose OKT3 induction appears to be safe and useful method of postoperative immunosuppression after liver transplantation. Its ultimate clinical, immunologic, and ecomic effecacy awaits determination by randomized trial.

AB - Background. A pilot study was performed to prospectively evaluate the safety and efficacy of 'low-lose ORTS induction after liver transplantation. Methods. Sixteen patients received a 5- to 10-day course of OKTS (2.5 mg i.v. daily) along with azathioprine, prednisone, and the delayed introduction of cyclosporine (Neoral). Results. Patient and graft survival rates at 1 year were 88% and 82%. Five patients (31%) heal biopsyproven rejection; all five were treated successfully with steroids. There were 15 infections in 12 patients including 5 cytomegalovirus infections. Adverse events attributed to OKT3 consisted of low-grade fever (five patients), transient hypoxemia (three patients), and transient hypotension (two patients). Pharmacy aquisition costs for OKT3 averaged $ 2,139 less as compared to a group of historical controls receiving full-dose therapy. Conclusions. Low-dose OKT3 induction appears to be safe and useful method of postoperative immunosuppression after liver transplantation. Its ultimate clinical, immunologic, and ecomic effecacy awaits determination by randomized trial.

UR - http://www.scopus.com/inward/record.url?scp=0032570753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032570753&partnerID=8YFLogxK

U2 - 10.1097/00007890-199802270-00022

DO - 10.1097/00007890-199802270-00022

M3 - Article

C2 - 9500637

AN - SCOPUS:0032570753

VL - 65

SP - 577

EP - 580

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 4

ER -